Takeda signs US$600M AI drug discovery deal with Insilico

1Key Takeaways

• Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas.
• The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration.
• The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target ….